KRT18 and metabolic dysfunction-associated steatohepatitis: CK-18 recently received independent validation for diagnosing NASH in a 2010 meta-analyses, where pooled AUROC, sensitivity and specificity for NASH were 0.82 (0.78–0.88), 0.78 (0.64–0.92), and 0.87 (0.77–0.98) respectively.85 An AUROC of 0.88 for diagnosis of NASH was also demonstrated in a morbidly obese population where, in addition, CK-18 levels were observed to fall significantly following bariatric surgery.138 Younossi et al. evaluated the diagnostic utility of several ELISA-based assays in patients with biopsy-proven NASH.